| | | | |
CUSIP No. 89854M101 | | SCHEDULE 13G | | Page 6 of 9 Pages |
Item 1. Issuer
TScan Therapeutics, Inc. (the “Issuer”)
| (b) | Address of Issuer’s Principal Executive Offices: |
830 Winter Street
Waltham, Massachusetts 02451
Item 2(a). Name of Person Filing:
This statement is being filed by the following persons with respect to the shares of Common Stock, par value $0.0001 per share (the “Shares”), directly owned by Bessemer Venture Partners IX L.P. (“BVP IX”) and Bessemer Venture Partners IX Institutional L.P. (“BVP IX Institutional” and together with BVP IX, the “Funds”).
(a) | Deer IX & Co. Ltd. (“Deer IX Ltd”), the general partner of Deer IX & Co. L.P. (“Deer IX LP”); |
(b) | Deer IX LP, the sole general partner of each of the Funds; |
(c) | BVP IX, which directly owns 691,505 Shares; and |
(d) | BVP IX Institutional, which directly owns 554,000 Shares. |
Deer IX Ltd, Deer IX LP, BVP IX and BVP IX Institutional are sometimes individually referred to herein as a “Reporting Person” and collectively as the “Reporting Persons.”
Item 2(b). Address of Principal Business Office or, if None, Residence:
The address of the principal business office of each of the Reporting Persons:
c/o Bessemer Venture Partners
1865 Palmer Avenue; Suite 104
Larchmont, NY 10583
Item 2(c). Citizenship:
Deer IX Ltd— Cayman Islands
Deer IX LP — Cayman Islands
BVP IX — Cayman Islands
BVP IX Institutional — Cayman Islands
Item 2(d). Title of Class of Securities:
Common Stock, par value $0.0001 per share
Item 2(e). CUSIP Number:
89854M101
Item 3. Not Applicable.